News & Analysis on Clinical Trial Services & Contract Research And Development
Maxim Pharmaceuticals has been issued with a US patent that covers a novel class of potent apoptosis inducers with vascular targeting activity that inhibits microtubule formation - a prime drug target in the fight against cancer.
Scientists from the University of California have discovered three molecules that show great potential in the development of new Alzheimer's drugs. The new therapy targets a protein that accumulates in Alzheimer's victims effectively curing the patient.
Lab and process equipment company Sartorius closed the first half of 2005 with increases in sales revenue and earnings, with a good performance by its filter business driven by demand from the biopharmaceutical industry.
UK company Diurnal has received orphan product designation from the European Commission for a novel treatment that uses a drug delivery technology to match the body's circadian rhythms.
Buck Systems, part of Niro Pharma Systems, has launched a laboratory-scale blender that allows users to analyse powders as they are being blended and monitor changing powder characteristics, achieving the ideal blend as quickly and economically as...
Chiron says it will be unable to supply any Begrivac influenza vaccine to markets outside the US during the 2005/6 flu season, just days after admitting it has sterility problems at a manufacturing plant.
NanoDrop Technologies has introduced a fluorospectrometer to its line of analytical instruments that allow researchers to measure ever-smaller sample amounts making it ideal for today's drug research environment.
The world's biggest maker of birth-control pills, Schering AG, has unveiled its second-quarter profit for 2005, which saw the drugmaker's profits rise by 34 per cent, helped by sales of its Yasmin contraceptive and gains from the sale of its stake in...
Chemicals and pharmaceuticals firm Merck KGaA saw turnover rise but pretax earnings dip in the second quarter of 2005, although the results were skewed by the gain from its divestment of its laboratory distribution business VWR International.